Eloralintide Peptide Therapy
Benefits, Side Effects, Cost & Protocols
Eloralintide is an investigational dual amylin and calcitonin receptor agonist being studied for weight management. It works by reducing appetite and slowing gastric emptying through amylin-pathway mechanisms that complement GLP-1-based therapies.
Clinically Reviewed
Reviewed by Alex Evans, PharmD, MBA · Updated May 2026
Evidence-Based
Sourced from FDA, PubMed & ClinicalTrials.gov · View sources
How Eloralintide Works
Amylin receptor agonist that promotes satiety and reduces food intake through a pathway distinct from GLP-1 signaling.
Eloralintide FAQ
What is ELORALINTIDE?
Eloralintide (LY3841136) is an investigational amylin receptor agonist being developed by Eli Lilly for weight management. It targets the amylin pathway, which is distinct from GLP-1 approaches.
How does ELORALINTIDE work?
Amylin receptor agonist that promotes satiety and reduces food intake through a pathway distinct from GLP-1 signaling.
Is ELORALINTIDE legal to buy?
ELORALINTIDE is sold as a research chemical for laboratory use only. It is not approved for human use by the FDA. Regulations vary by jurisdiction.
Where can I buy ELORALINTIDE?
ELORALINTIDE is available as a research compound from verified online vendors. Always verify third-party testing before purchasing.
What category does ELORALINTIDE belong to?
ELORALINTIDE is primarily classified as a weight loss & metabolic peptide. Peptides researched for their effects on weight management, fat metabolism, appetite regulation, and metabolic enhancement. This category includes GLP-1 agonists, dual/triple agonists, and other metabolic peptides.
What are the research benefits of ELORALINTIDE?
ELORALINTIDE has been studied for: Weight loss potential, Appetite regulation via amylin pathway, Novel mechanism of action. Eli Lilly investigational compound. Targets amylin pathway distinct from GLP-1.
Key Studies
5 total on PubMed0Eloralintide, a selective, long-acting amylin receptor agonist for treatment of obesity: Phase 1 proof of concept
Bhattachar S, Tham LS, Tidemann-Miller B et al
Diabetes Obes Metab · Diabetes Obes MetabPhase 1
Eloralintide, a long-acting amylin agonist, shows proof of concept for obesity
Eloralintide, a selective amylin receptor agonist for the treatment of obesity: a 48-week phase 2, multicentre, double-blind, randomised, placebo-controlled trial
Billings LK, Hsia S, Bays H et al
LancetPhase 2
Eloralintide demonstrates efficacy in obesity treatment in phase 2 randomized trial
Eloralintide (LY3841136), a novel amylin receptor agonist for the treatment of obesity: From discovery to clinical proof of concept
Briere DA, Qu H, Lansu K et al
Mol Metab · Mol Metab
Eloralintide, a novel amylin receptor agonist, shows potential for obesity treatment
Eloralintide News
Oral Small Molecule Amylin Receptor Agonist ASC39 Demonstrated Eloralintide-like Amylin Selectivity and Efficacy in Preclinical Models - PR Newswire
PR Newswire · 2 months ago
New GLP-1 alternative, eloralintide, leads to 20% weight loss in trial - Medical News Today
Medical News Today · 5 months ago
Ascletis Pharma selects ASC-39 as clinical development candidate - BioWorld News
BioWorld News · 2 months ago
Ascletis Pharma’s ASC39 Oral Amylin Receptor Agonist Shows Eloralintide-Like Efficacy and Selectivity for Obesity Treatment in Preclinical Models 123 - Minichart
Minichart · 2 months ago
Amylin Analog Eloralintide Reduces Weight in Phase 2 Trial - Medscape
Medscape · 6 months ago
Ascletis to Present Data on Multiple Programs at the American Diabetes Association's 2026 Scientific Sessions - Morningstar
Morningstar · 19 days ago
Strategic applications of methylene thioacetal bonds as disulfide surrogates in peptide drug discovery - Frontiers
Frontiers · 10 months ago
New weight-loss shot shows major fat reduction, but experts urge caution - Fox News
Fox News · 5 months ago
News aggregated via Google News. Inclusion does not imply endorsement.
Ready to explore Eloralintide with a provider?
Take our 2-minute quiz to get matched with a board-certified provider specializing in Eloralintide.
Take the Quiz →